Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study

Revefenacin is a novel once‐daily, lung‐selective, long‐acting muscarinic antagonist developed as a nebulized inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease. In a randomized, 4‐way crossover study, healthy subjects received a single inhaled dose of revefen...

Descripción completa

Detalles Bibliográficos
Autores principales: Borin, Marie T., Barnes, Chris N., Darpo, Borje, Pendyala, Srikanth, Xue, Hongqi, Bourdet, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004040/
https://www.ncbi.nlm.nih.gov/pubmed/31468714
http://dx.doi.org/10.1002/cpdd.732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004040/
https://www.ncbi.nlm.nih.gov/pubmed/31468714
http://dx.doi.org/10.1002/cpdd.732

Ejemplares similares